Antibiotic product, use and formulation thereof
View Patent ↗An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the C max for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there is a delayed release dosage form, as well as two or more delayed sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a C max at different times.
1. A once-a-day antibiotic product comprising: first, second, and third antibiotic dosage forms, each of said antibiotic dosage forms comprising at least one antibiotic and a pharmaceutically acceptable carrier, said first antibiotic dosage form being a delayed release dosage form, said second and third antibiotic dosage forms being delayed sustained release dosage forms, wherein said second dosage form comprises immediate release component beads coated with a sustained release coating and a delayed release coating or sustained release matrix component beads coated with a delayed release coating and initiates release of antibiotic at about the same time as said first dosage form initiates release of antibiotic or wherein said second dosage form initiates release of antibiotic after said first dosage form initiates release of antibiotic, and wherein said third dosage form comprises immediate release component beads coated with a sustained release coating and a delayed release coating or sustained release matrix component beads coated with a delayed release coating and initiates release of antibiotic after said second dosage form initiates release of antibiotic, and Cmax of the total antibiotic released from said antibiotic product is achieved in less than about 12 hours from initial release of antibiotic and said once-a-day antibiotic product contains the total dosage of the at least one antibiotic for a twenty-four hour period.
2. The product of claim 1 , wherein said second dosage form initiates release of antibiotic at about the same time as said first dosage form initiates release of antibiotic.
3. The product of claim 1 , wherein said second dosage form initiates release of antibiotic after said first dosage form initiates release of antibiotic.
4. The product of claim 1 , wherein the Cmax for the product is reached no earlier than four hours after initial release of antibiotic.
5. The product of claim 1 , wherein the antibiotic released from the first dosage form reaches a Cmax within from about 0.5 hours to about 2 hours after initial release of antibiotic.
6. The product of claim 1 , wherein the product is an oral dosage form.
7. The product of claim 1 , wherein the antibiotic released from the second dosage form reaches a Cmax after Cmax is reached for the antibiotic released from the first dosage form.
8. The product of claim 1 , wherein the antibiotic released from the third dosage form reaches a Cmax after Cmax is reached for the antibiotic released from the second dosage form.
9. The product of claim 1 , wherein the first dosage form contains about 20-70% of the total dosage of antibiotic, the second dosage form contains about 10-70% of the total dosage of antibiotic, and the third dosage form contains about 10-70% of the total dosage of antibiotic.
10. The product of claim 1 , wherein the first dosage form contains about 25-66% of the total dosage of antibiotic, the second dosage form contains about 15-60% of the total dosage of antibiotic, and the third dosage form contains about 15-60% of the total dosage of antibiotic.
11. The product of claim 1 , wherein the first dosage form contains about 33-60% of the total dosage of antibiotic, the second dosage form contains about 25-50% of the total dosage of antibiotic, and the third dosage form contains about 25-50% of the total dosage of antibiotic.
12. The product of claim 1 further comprising a fourth antibiotic dosage form, said fourth antibiotic dosage form being either a sustained or a delayed release dosage form and comprising at least one antibiotic and a pharmaceutically acceptable carrier and wherein said at least one antibiotic released from said fourth antibiotic dosage form reaches a Cmax after Cmax is achieved for antibiotic released from each of said first, second, and third dosage forms.
13. The product of claim 12 , wherein the Cmax for the product is reached no earlier than four hours after initial release of antibiotic.
14. The product of claim 12 , wherein the antibiotic released from the first dosage form reaches a Cmax within from about 0.5 hours to about 2 hours after initial release of antibiotic.
15. The product of claim 12 , wherein the antibiotic released from the second dosage form reaches a Cmax in no more than about 4 hours after initial release of antibiotic.
16. The product of claim 12 , wherein the product is an oral dosage form.
17. The product of claim 12 , wherein the antibiotic released from the second dosage form reaches a Cmax after Cmax is reached for the antibiotic released from the first dosage form.
18. The product of claim 12 , wherein the antibiotic released from the third dosage form reaches a Cmax after Cmax is reached for the antibiotic released from the second dosage form.
19. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 1 , once-a-day.
20. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 2 , once-a-day.
21. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 3 , once-a-day.
22. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 4 , once-a-day.
23. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 5 , once-a-day.
24. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 6 , once-a-day.
25. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 7 , once-a-day.
26. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 8 , once-a-day.
27. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 9 , once-a-day.
28. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 10 , once-a-day.
29. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 11 , once-a-day.
30. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 12 , once-a-day.
31. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 13 , once-a-day.
32. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 14 , once-a-day.
33. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 15 , once-a-day.
34. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 16 , once-a-day.
35. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 17 , once-a-day.
36. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 18 , once-a-day.
37. The product of claim 1 , wherein said delayed release dosage form, which is the first of said first, second, and third antibiotic dosage forms, comprises an immediate release dosage form and a member independently selected from the group consisting of: pH-sensitive components and non-pH-sensitive components, to delay the release of the antibiotic therefrom.
38. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 37 , once-a-day.
39. The product of claim 1 , wherein said antibiotic is amoxicillin.
40. The product of claim 1 , wherein said antibiotic is cephalexin.
41. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 39 , once-a-day.
42. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 40 , once-a-day.